Breaking News Instant updates and real-time market news.

ABBV

AbbVie

$60.14

-0.03 (-0.05%)

, ABT

Abbott

$40.59

-0.2 (-0.49%)

04:55
10/18/16
10/18
04:55
10/18/16
04:55

American Academy of Ophthalmology to hold a conference

AAO 2016 is being held in Chicago on October 15-18.

ABBV

AbbVie

$60.14

-0.03 (-0.05%)

ABT

Abbott

$40.59

-0.2 (-0.49%)

ADVM

Adverum Biotechnologies

$3.37

-0.2 (-5.60%)

BABY

Natus Medical

$40.15

-0.5 (-1.23%)

CAJ

Canon

$28.95

0.14 (0.49%)

CLSD

Clearside Biomedical

$21.23

1.07 (5.31%)

DGX

Quest Diagnostics

$83.04

-0.13 (-0.16%)

ITEK

Inotek Pharmaceuticals

$7.95

0.22 (2.85%)

MNK

Mallinckrodt

$64.96

-0.86 (-1.31%)

NBY

NovaBay

$3.91

-0.0101 (-0.26%)

OCUL

Ocular Therapeutix

$6.55

-0.24 (-3.53%)

SHPG

Shire

$185.79

-1.91 (-1.02%)

STAA

STAAR Surgical

$9.45

0.25 (2.72%)

  • 19

    Oct

  • 19

    Oct

  • 20

    Oct

  • 26

    Oct

  • 26

    Oct

  • 28

    Oct

  • 06

    Nov

  • 11

    Nov

  • 29

    Nov

  • 14

    Dec

ABBV AbbVie
$60.14

-0.03 (-0.05%)

10/03/16
LEER
10/03/16
NO CHANGE
LEER
Market Perform
AASLD abstracts hint at potential competitive threat to Gilead HCV, says Leerink
Leerink analyst Geoffrey Porges says abstracts for the American Association for the Study of Liver Diseases, or AASLD, meeting revealed very limited efficacy information about the new Hepatitis C regimens for Gilead (GILD), Merck (MRK) and AbbVie (ABBV). Nonetheless, the analyst believes the abstracts hint at the potential competitive threat to Gilead's HCV dominance. While the new 12-week HCV regimens may compete on price, the forthcoming 8-week regimens put the most pressure on Gilead's market share, Porges argues. He reiterates a Market Perform rating on Gilead's shares.
09/08/16
JPMS
09/08/16
DOWNGRADE
Target $73
JPMS
Neutral
AbbVie downgraded to Neutral from Overweight at JPMorgan
JPMorgan analyst Chris Schott downgraded AbbVie (ABBV) to Neutral citing the stock's 10% rally year-to-date and limited near-term catalysts. AbbVie's profile is now better reflected at current valuation levels, Schott tells investors in a research note. He lowered his price target for the shares to $73 from $75. The analyst coupled the downgrade with an upgrade this morning of Eli Lilly (LLY) to Overweight.
10/12/16
RBCM
10/12/16
NO CHANGE
RBCM
Outperform
Vertex competitor to report data soon, but has long way to go, says RBC Capital
RBC Capital analyst Michael Yee noted that Galapagos NV (GLPG) and partner AbbVie (ABBV) are likely to present new Phase IIa data for GLP-1837 for cystic fibrosis and host an analyst event on October 27, adding that he believes the data will likely be positive and suggest they are "on track" with progress on their triple pill. Yee adds it won't be surprising if Galapagos has positive '1837 "potentiator" data, as this is the easier of the components and only the first piece of a 3-pill drug. Vertex (VRTX) is also hosting an analyst event on Oct. 27 and will probably also give an update on its own "triple," said Yee, who thinks it should stay in the lead with most advanced triple. Yee keeps an Outperform rating on Vertex shares.
10/13/16
JEFF
10/13/16
DOWNGRADE
Target $36
JEFF
Hold
Pfizer downgraded to Hold from Buy at Jefferies
Jefferies analyst Jeffrey Holford downgraded Pfizer (PFE) to Hold citing a lack of positive catalysts. The analyst says the drivers for his upgrade to Buy have either played out or have not materialized, namely an inversion or GEP unit separation. To reflect the infusion business disposal and weaker Ibrance trends, Holford cut his mid-term earnings estimates for Pfizer by up to 7% and cut his price target for the shares to $36 from $39. The stock closed yesterday down 6c to $33.07. The analyst also sees increased risk of a major acquisition occurring over the next 12 months. In the global pharma space, Holford lists AbbVie (ABBV), Eli Lilly (LLY), Novartis (NVS) and AstraZeneca (AZN) as his top picks.
ABT Abbott
$40.59

-0.2 (-0.49%)

09/29/16
ADAM
09/29/16
NO CHANGE
Target $53
ADAM
Buy
Alere risk-reward looks 'quite good' as deal debate nears end, says Canaccord
Canaccord analyst Mark Massaro said he is optimistic that a conclusion of Abbott (ABT) and Alere's (ALR) merger fight is "not far off" and he still believes Abbott will ultimately acquire Alere, though he also thinks the merger may be decided by a judge. Massaro puts a 65% probability on the likelihood the deal closes at the $56 deal price, a 30% chance that Abbott buys Alere at a lower price nearer to $50 per share, and only a 5% chance the deal breaks, making the risk-reward ratio in Alere shares at current levels "quite good," he tells investors. He trimmed his price target on Alere to $53 from $56 an keeps a Buy rating on the stock.
09/29/16
BARD
09/29/16
NO CHANGE
BARD
Dexcom, Insulet could be weighed down by competitive concerns, says Baird
Baird analyst Jeff Johnson said that while the FDA approvals announced yesterday for Abbott's (ABT) FreeStyle Libre Pro and Medtronic's (MDT) 670G were largely anticipated, he believes that both approvals came sooner than most expected, as did news that Abbott also recently filed for FDA approval of its consumer Libre system. The approvals could "change the narrative" in diabetes and could weigh on others in the sector in the near-term, most notably Dexcom (DXCM) and Insulet (PODD), Johnson tells investors. He keeps Neutral ratings on both and maintains an Overweight rating on Tandem Diabetes (TNDM), citing valuation for the difference.
10/11/16
COWN
10/11/16
NO CHANGE
Target $85
COWN
Outperform
Cowen says St. Jude advisory common for the industry
While Dear Doctor letters are never a positive, St. Jude Medical's (STJ) medical device advisory relating to a low rate of premature battery depletion in the high voltage portfolio is common in the Cardiac Rhythm Management industry, Cowen analyst Joshua Jennings tells investors in a research note. The analyst sees limited risk to St. Jude's franchise and still expects the takeover by Abbott Laboratories' (ABT) to close by the end of the year. Jennings keeps an Outperform rating on St. Jude shares with an $85 price target. The stock is down 1% to $80.19 in pre-market trading.
09/29/16
COWN
09/29/16
NO CHANGE
COWN
Outperform
Cowen says views on Dexcom, Insulet not changed by competitor launches
Cowen analyst Doug Schenkel noted that Abbott (ABT) announced yesterday it had received FDA approval for the professional version of its FreeStyle Libre glucose monitoring product and filed the consumer version of Libre, while Medtronic (MDT) also announced FDA approval of its 670G Hybrid Closed Loop system. Schenkel said Abbott's consumer Libre filing comes a few months ahead of his expectations but that Medtronic's timing was in-line with expectations. The analyst said the competitor announcements, which had been expected, do not change his views on DexCom (DXCM), Insulet (PODD), or Tandem Diabetes (TNDM) and he keeps Outperform ratings on all three of those stocks.
ADVM Adverum Biotechnologies
$3.37

-0.2 (-5.60%)

05/27/16
COWN
05/27/16
INITIATION
COWN
Outperform
Adverum Biotechnologies reinstated with an Outperform at Cowen
Cowen reinstated Adverum Biotechnologies with an Outperform rating after the closing of its acquisition of Annapurna. The firm sees several key upcoming events and expects the shares to outperform should any of its programs progress through clinical development.
06/08/16
CHDN
06/08/16
DOWNGRADE
Target $5
CHDN
Neutral
Adverum Biotechnologies downgraded to Neutral from Buy at Chardan
BABY Natus Medical
$40.15

-0.5 (-1.23%)

10/04/16
BNCH
10/04/16
INITIATION
Target $55
BNCH
Buy
Natus Medical initiated with a Buy at Benchmark
Benchmark analyst Raymond Myers started Natus Medical with a Buy rating and $55 price target.
09/26/16
ROTH
09/26/16
NO CHANGE
Target $47
ROTH
Buy
Otometrics acquisition positive for Natus Medical, says Roth Capital
Roth Capital analyst Chris Lewis notes that Natus Medical announced the acquisition of Otometrics for $145M and an expected Q3 revenue shortfall. While the analyst is disappointed with the shortfall, he believes the main driver is transient in nature and should pass by the beginning of 2017. Further, Lewis sees the Otometrics acquisition as a "meaningful positive" for Natus Medical as it significantly expands the company and should allow it to reach $500M in annual revenues in 2017. He reiterates a Buy rating and $47 price target on the shares.
09/13/16
RAJA
09/13/16
UPGRADE
Target $46
RAJA
Outperform
Natus Medical upgraded to Outperform on earnings power at Raymond James
As previously reported, Raymond James analyst Jayson Bedford upgraded Natus Medical to Outperform from Market Perform with a $46 price target. Bedford recently met with management and came away more confident that capital deployment will be larger than expected, potentially increasing earnings meaningfully and acting as a catalyst for shares. He believes Natus will likely add businesses that are adjacent to their core Neurology and Newborn businesses, and would not be surprised to see it carve out a non-core business from a larger entity.
09/13/16
RAJA
09/13/16
UPGRADE
RAJA
Outperform
Natus Medical upgraded to Outperform from Market Perform at Raymond James
CAJ Canon
$28.95

0.14 (0.49%)

07/15/16
LYON
07/15/16
DOWNGRADE
LYON
Underperform
Canon downgraded to Underperform from Buy at CLSA
CLSA analyst Claudio Aritomi downgraded Canon to Underperform from Buy saying there is a high probability Canon will cut its guidance for FY16 along with 2Q results.
11/20/15
11/20/15
DOWNGRADE

On The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: Airgas (ARG) downgraded to Hold from Buy at Jefferies... Akamai (AKAM) downgraded to Sell from Neutral at Goldman... American Woodmark (AMWD) downgraded to Neutral at Baird... Autodesk (ADSK) downgraded to Sector Perform from Outperform at RBC Capital... Barclays (BCS) downgraded to Equal Weight from Overweight at Morgan Stanley... Bed Bath & Beyond (BBBY) downgraded to Hold from Buy at Cantor... CIBC (CM) downgraded to Sector Perform from Outperform at Scotia Howard Weil... Canon (CAJ) downgraded to Neutral from Outperform at Macquarie... Chart Industries (GTLS) downgraded to Neutral from Overweight at Piper Jaffray... Cloud Peak (CLD) downgraded to Sell from Buy at UBS... Cnova (CNV) downgraded to Neutral from Overweight at JPMorgan... Diana Containerships (DCIX) downgraded to Underperform at Wells Fargo... Diana Shipping (DSX) downgraded to Market Perform from Outperform at Wells Fargo... Eagle Materials (EXP) downgraded to Neutral from Buy at Goldman... El Paso Electric (EE) downgraded to Underperform from Hold at Jefferies... Express (EXPR) downgraded to Sell from Neutral at Goldman... Fidelity & Guaranty Life (FGL) downgraded to Sector Perform from Outperform at RBC Capital... Grifols (GRFS) downgraded to Hold from Buy at Berenberg... Hanmi Financial (HAFC) downgraded to Neutral from Overweight at Piper Jaffray... Hawaiian Electric (HE) downgraded to Market Perform from Outperform at Wells Fargo... K+S (KPLUF) downgraded to Underperform from Neutral at Credit Suisse... Mentor Graphics (MENT) downgraded to Hold from Buy at Needham... Nimble Storage (NMBL) downgraded to Sector Weight from Overweight at Pacific Crest... Peabody (BTU) downgraded to Sell from Neutral at UBS... PolyOne (POL) downgraded to Neutral from Accumulate at Seaport Global... Restoration Hardware (RH) downgraded to Neutral from Buy at Goldman... Sanderson Farms (SAFM) downgraded to Neutral from Buy at Sidoti... Seaspan (SSW) downgraded to Market Perform from Outperform at Wells Fargo... SunEdison (SUNE) downgraded to Neutral from Overweight at JPMorgan... Williams-Sonoma (WSM) downgraded to Buy from Conviction Buy at Goldman... Workday (WDAY) downgraded to Neutral from Outperform at Wedbush.
11/20/15
MACQ
11/20/15
DOWNGRADE
MACQ
Neutral
Canon downgraded to Neutral from Outperform at Macquarie
01/07/16
JPMS
01/07/16
DOWNGRADE
JPMS
Neutral
Canon downgraded to Neutral from Overweight at JPMorgan
CLSD Clearside Biomedical
$21.23

1.07 (5.31%)

06/27/16
COWN
06/27/16
INITIATION
COWN
Outperform
Clearside Biomedical initiated with an Outperform at Cowen
Cowen analyst Boris Peaker initiated Clearside Biomedical with an Outperform rating following its IPO. The analyst noted the company is developing a novel device that enables the administration of drugs to the back of the eye with minimal front of the eye exposure which can be used for indications like AMD, DME, and glaucoma.
06/27/16
06/27/16
INITIATION

On The Fly: Top five analyst initiations
Catch up on the today's top five analyst initiations with this list compiled by The Fly: 1. Spectra Energy (SE) initiated with an Outperform at RBC Capital by analyst Elvira Scotto, who has a $39 price target on the stock. The analyst believes Spectra can deliver solid, highly visible cash-flow and dividend growth over the next several years underpinned by a robust backlog of demand-pull growth projects. 2. GW Pharmaceuticals (GWPH) initiated with a Sell at Janney Capital by analyst Ken Trbovich, who has a $40 price target on the stock. The analyst said GW awaits imminent results of Phase 3 trial results in Lennox-Gastaut Syndrome. Unfortunately, even if the data in LGS is good, Trbovich thinks its valuation exceeds the commercial prospects for drugs that treat orphan epilepsy indications.3. NantHealth (NH) initiated with a Buy at Canaccord by analyst Richard Close, who has a $17 price target following its recent IPO. The firm sees NantHealth as a leader in precision medicine, bringing to market an innovative cancer diagnostic test coupled with a cloud-based offering to drive increased value. NantHealth was also initiated with an Outperform at FBR Capital and Cowen and an Ovweight at First Analysis, with analyst Joseph Munda saying he believes the company has assembled a powerful combination of information technology and advanced molecular diagnostics and views its leadership as exceptionally well qualified. 4. Skyworks (SWKS) initiated with an Underweight at Morgan Stanley by analysts led by Craig Hettenbach, who put a $61 price target on the stock. The analyst said Skyworks is far behind Broadcom on business diversification and customer concentration will likely pressure the stock's multiple. 5. Clearside Biomedical (CLSD) initiated with an Outperform at Cowen by analyst Boris Peaker, who noted the company is developing a novel device that enables the administration of drugs to the back of the eye with minimal front of the eye exposure which can be used for indications like AMD, DME, and glaucoma. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/27/16
STFL
06/27/16
INITIATION
STFL
Buy
Clearside Biomedical initiated with a Buy at Stifel
Target $13.
DGX Quest Diagnostics
$83.04

-0.13 (-0.16%)

09/09/16
SBSH
09/09/16
INITIATION
Target $86
SBSH
Neutral
Quest Diagnostics initiated with a Neutral at Citi
Citi analyst Ralph Giacobbe started Quest Diagnostics with a Neutral rating and $86 price target. The analyst views the valuation as fair given the questions around growth drivers.
09/13/16
CHLM
09/13/16
NO CHANGE
CHLM
LabCorp impact from Quest-Optum collaboration limited, says Craig-Hallum
Craig-Hallum analyst Bill Bonello said the Quest Diagnostics (DGX) and Optum, a division of United Healthcare (UNH), collaboration does not put LabCorp's (LH) revenue at risk. The collaboration does not create any lab benefit management service, or a preferred lab network with Quest at the hub, that would drive business to Quest labs or compete with Labcorp's Beacon LBS lab management business, the analyst wrote. Bonellow said UnitedHealthcare and LabCorp continue to work together to expand the Beacon LBS model to other markets and we would expect to see the Beacon lab network expand to other payors overtime. Also, the analyst said the collaboration does not impact LabCorp's contract with UnitedHealthcare, or UHC, and and has no impact on that contract today and does not imply a change to UHC's contracting strategy going forward. Bonello rates LabCorp a Buy with a $160 price target.
09/14/16
ADAM
09/14/16
NO CHANGE
Target $155
ADAM
Buy
LabCorp weakness a buying opportunity, says Canaccord
Canaccord analyst Mark Massaro noted LabCorp (LH) shares sold off yesterday on news that its rival, Quest Diagnostics (DGX), announced a partnership with Optum, a subsidiary of UnitedHealth (UNH). The analyst said LabCorp does not believe Quest can wrestle away UnitedHealth's long-standing lab services contract when it goes up for renewal in 2018. Massaro expects LabCorp to deliver steady quarterly beats and said the company is well positioned to capture its losses in the second half of 2016. Massaro reiterated his Buy rating and $155 price target on LabCorp shares.
08/31/16
08/31/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Under Armour (UA) downgraded to Hold from Buy at Argus by John Staszak, based on his belief that the company will have to make significant investments to expand its business going forward. 2. First Solar (FSLR) downgraded to Hold from Buy at Argus by analysts Stephen Biggar and Jasper Hellweg, citing what they see as the company's lack of earnings visibility. The analysts say that the company's backlog is falling, while it is encountering "intense price competition." 3. Palo Alto Networks (PANW) downgraded to Outperform from Strong Buy at Raymond James by analyst Michael Turits, citing the company's weaker than expected guidance for FY17. Palo guided product growth to 12%-13%, nearly halfway below the consensus estimate of 22%, said Turits, who lowered his price target for the shares to $165 from $180. 4. G-III Apparel (GIII) downgraded to Sell from Hold at Stifel. Despite the recent decline in the stock, its risk/reward ratio is unfavorable given the multiple risks faced by the company, according to Stifel analyst Jim Duffy. 5. Quest Diagnostics (DGX) downgraded to Neutral from Buy at Mizuho. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
ITEK Inotek Pharmaceuticals
$7.95

0.22 (2.85%)

09/20/16
HCWC
09/20/16
INITIATION
Target $22
HCWC
Buy
Inotek Pharmaceuticals initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Corey Davis started Inotek Pharmaceuticals with a Buy rating and $22 price target.
10/10/16
PIPR
10/10/16
NO CHANGE
Target $24
PIPR
Overweight
Inotek CSO departure does not reflect ongoing trial, says Piper Jaffray
After speaking with Inotek Pharmaceuticals, Piper Jaffray analyst Joshua Schimmer believes the departure of Chief Scientific Officer Bill McVicar "in no way" reflects on the ongoing Phase III trabodenoson trial in glaucoma. The analyst continues to see a favorable risk/reward heading into the data, which are expected by year-end. He keeps an Overweight rating on Inotek with a $24 price target.
MNK Mallinckrodt
$64.96

-0.86 (-1.31%)

08/24/16
PIPR
08/24/16
NO CHANGE
Target $112
PIPR
Overweight
Mallinckrodt price target raised to $112 from $103 at Piper Jaffray
Piper Jaffray analyst David Amsellem said his talks with Mallinckrodt management indicate that the company's contracting activity is providing greater standardization of Acthar coverage and generally making the process of getting an Acthar prescription filled more predictable. In turn, this should make it more likely that physicians and practices will more consistently prescribe the drug, Amsellem tells investors. Paired with additional clinical outcomes data, Amsellem sees high visibility for relatively strong volume growth over the long-term and raised his price target on Mallinckrodt shares to $112 from $103 while keeping an Overweight rating on the stock.
08/18/16
08/18/16
NO CHANGE

Mallinckrodt building new campus for Specialty Brands business in New Jersey
Mallinckrodt will build out a new campus for its Specialty Brands organizations in the Somerset Financial Center in Bedminster. Mallinckrodt will invest greater than $80M in New Jersey, and anticipates approximately 400 employees will occupy the new space in 1Q17. The company is also continuing its investment in St. Louis, Mo., having recently begun the next phase of construction at its downtown St. Louis manufacturing facility.
08/26/16
UBSW
08/26/16
NO CHANGE
Target $92
UBSW
Buy
Skepticism on Acthar growth already priced into Mallinckrodt shares, says UBS
UBS analyst Marc Goodman said his investment thesis on Mallinckrodt remains unchanged, as he still sees an attractive valuation, has expectations its generics business will stabilize and believes that skepticism surrounding Acthar's growth is already priced into the stock. Goodman reiterated his Buy rating and $92 price target on Mallinckrodt shares.
09/21/16
MSCO
09/21/16
NO CHANGE
MSCO
Mallinckrodt's Ikaria acquisition underappreciated, says Morgan Stanley
Morgan Stanley analyst David Risinger said since the closing of the Ikaria acquisition, Mallinckrodt has quietly grown to be approximately 15% of 2017 estimates revenues and approximately 25% of 2017 estimated operating income. Given Ikaria's strong growth trends, Risinger estimates its valuation to be in the range of $3.9B-$4.3B, excluding Terlipressin pipeline asset, 78% more at the midpoint than Mallinckrodt's $2.3B purchase price.
NBY NovaBay
$3.91

-0.0101 (-0.26%)

03/08/16
MAXM
03/08/16
DOWNGRADE
MAXM
Hold
NovaBay downgraded to Hold from Buy at Maxim (yesterday)
Maxim analyst Jason Kolbert downgraded NovaBay Pharmaceuticals yesterday to Hold citing the company's "weak" balance sheet. Avenova sales are not growing fast enough for the company to reach breakeven "anytime in the next few years," Kolbert told investors in a research note.
03/07/16
MAXM
03/07/16
DOWNGRADE
MAXM
Hold
NovaBay downgraded to Hold from Buy at Maxim
OCUL Ocular Therapeutix
$6.55

-0.24 (-3.53%)

06/07/16
MSCO
06/07/16
NO CHANGE
Target $16
MSCO
Overweight
Ocular Therapeutix weakness an overreaction, says Morgan Stanley
Morgan Stanley analyst Andrew Berens said the initial investor reaction to the failure of the second Phase III trial for Dextenza in allergic conjunctivitis appears extreme. Berens said he assigned little direct value for the allergy opportunity and does not see a read through to the post-op indication. The analyst said the focus remains on Dextenza's July 24 PDUFA in post surgical pain and maintains his Overweight rating on Ocular and $16 price target.
07/26/16
RBCM
07/26/16
NO CHANGE
RBCM
Ocular Therapeutix risk/reward still positive, says RBC Capital
After the FDA issued a complete response letter for Ocular's Dextenza, RBC Capital analyst Adnan Butt notes that the agency did not ask for more safety or efficacy data about the drug. According to the analyst, the company has already issued a response to the letter, and the FDA's reply could come in one to three months. Butt thinks that the stock could still advance if Dextenza and a number of its other drugs are approved. The analyst trimmed the price target on the shares to $38 from $40 but keeps an Outperform rating on the stock.
08/11/16
JMPS
08/11/16
INITIATION
Target $21
JMPS
Outperform
Ocular Therapeutix initiated with an Outperform at JMP Securities
Target $21.
10/13/16
BTIG
10/13/16
NO CHANGE
Target $18
BTIG
Buy
Ocular deal with Regeneron has favorable terms, says BTIG
BTIG analyst Ling Wang believes Ocular Therapeutix's (OCUL) strategic collaboration with Regeneron (REGN) comes with favorable deal terms. The back-end loaded structure brings the potential for large upside, Wang tells investors in a research note. In addition, the partnership provides external validation for Ocular's platform technology, Wang adds. The analyst reiterates a Buy rating on the shares with an $18 price target
SHPG Shire
$185.79

-1.91 (-1.02%)

09/26/16
HSBC
09/26/16
DOWNGRADE
HSBC
Hold
Shire downgraded to Hold from Buy at HSBC
HSBC analyst Steve McGarry downgraded SHire to Hold saying valuation is no longer compelling.
08/03/16
LEER
08/03/16
NO CHANGE
Target $231
LEER
Outperform
Shire price target raised to $231 from $213 at Leerink
Leerink analyst Jason Gerberry raised his price target for Shire to $231 from $213 on valuation after the company reported "solid" Q2 results. The analyst reiterates an Outperform rating on the shares.
09/26/16
LEER
09/26/16
NO CHANGE
LEER
Shire Xiidra launch to 'significantly' expand dry eye category, says Leerink
Leerink analyst Jason Gerberry remains optimistic that Shire's (SHPG) Xiidra launch will "significantly" expand the category for dry eye disease brands, while not meaningfully eroding Allergan's (AGN) Restasis market leading position. While it's still early in the launch of Xiidra and payer access remains a critical variable, the analyst does not anticipate access being a major barrier. Gerberry reiterates an Outperform rating on both Shire and Allergan's shares.
08/31/16
JEFF
08/31/16
NO CHANGE
Target $262
JEFF
Buy
Shire making right moves in dry eye market, says Jefferies
After hosting meetings with management, Jefferies analyst David Steinberg believes Shire (SHPG) is making "all the right moves" to make its dry eye drug Xiidra a potential $2B peak product in the U.S. Shire's Xiidra is competing with Allergan's (AGN) $1.4B dry eye drug Restasis, Steinberg tells investors in a research note. The analyst does not think Shire will have any problem exceeding the drug's consensus sales forecast of $200M for next year. He keeps a Buy rating on the shares with a $262 price target.
STAA STAAR Surgical
$9.45

0.25 (2.72%)

05/12/16
SPHN
05/12/16
DOWNGRADE
Target $8
SPHN
Equal Weight
STAAR Surgical downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Chris Cooley downgraded STAAR Surgical to Equal Weight from Overweight as he believes the shares will remain range-bound in the near-term barring a favorable resolution of FDA remediation efforts and more clarity on its revised cataract franchise strategy. The analyst lowered his price target on the stock to $8 from $10.

TODAY'S FREE FLY STORIES

ATH

Athene Holding

10:25
12/09/16
12/09
10:25
12/09/16
10:25
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding opens at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

10:25
12/09/16
12/09
10:25
12/09/16
10:25
General news
The U.S. wholesale report beat estimates »

The U.S. wholesale report…

PSTG

Pure Storage

$12.26

-0.075 (-0.61%)

10:25
12/09/16
12/09
10:25
12/09/16
10:25
Conference/Events
Pure Storage participates in a conference call with UBS »

UBS IT Hardware & EMS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 12

    Dec

  • 12

    Jan

  • 13

    Jan

  • 09

    Dec

MEET

MeetMe

$5.47

0.28 (5.40%)

10:24
12/09/16
12/09
10:24
12/09/16
10:24
Conference/Events
MeetMe management to meet with Roth Capital »

Meeting to be held in St.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

DATA

Tableau

$45.85

0.2 (0.44%)

10:24
12/09/16
12/09
10:24
12/09/16
10:24
Rumors
Rumor moving shares of Tableau »

Rumor: Tableau moves up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ATH

Athene Holding

10:23
12/09/16
12/09
10:23
12/09/16
10:23
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

ICHR

Ichor Holdings

10:23
12/09/16
12/09
10:23
12/09/16
10:23
Syndicate
Ichor Holdings indicated to open at $9.75, IPO priced at $9.00 »

Ichor Holdings (ICHR)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CPB

Campbell Soup

$59.00

0.72 (1.24%)

10:21
12/09/16
12/09
10:21
12/09/16
10:21
Options
Campbell Soup calls are stirring »

Campbell Soup calls are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RH

Restoration Hardware

$32.75

-6.24 (-16.00%)

10:20
12/09/16
12/09
10:20
12/09/16
10:20
Options
Restoration Hardware options active as shares fall on earnings »

Restoration Hardware…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

10:20
12/09/16
12/09
10:20
12/09/16
10:20
General news
Treasury Action: yields remained subdued »

Treasury Action: yields…

CPK

Chesapeake Utilities

$68.55

0.55 (0.81%)

, CNX

CONSOL

$21.16

-0.62 (-2.85%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Initiation
On The Fly: Top five analyst initiations »

Catch up on today's…click here.

CPK

Chesapeake Utilities

$68.55

0.55 (0.81%)

CNX

CONSOL

$21.16

-0.62 (-2.85%)

JCI

Johnson Controls

$43.68

0.03 (0.07%)

AMID

American Midstream Partners

$16.95

-0.05 (-0.29%)

BIP

Brookfield Infrastructure

$32.93

0.2499 (0.76%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

ANF

Abercrombie & Fitch

$15.96

-0.28 (-1.72%)

, DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Downgrade
On The Fly: Top five analyst downgrades »

Catch up on today's…click here.

ANF

Abercrombie & Fitch

$15.96

-0.28 (-1.72%)

DLTH

Duluth Holdings

$37.04

3.09 (9.10%)

DTEA

DAVIDsTEA

$9.30

0.15 (1.64%)

HLT

Hilton

$26.54

0.295 (1.12%)

HZNP

Horizon Pharma

$15.03

-4.36 (-22.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

  • 14

    Dec

AZN

AstraZeneca

$27.11

0.84 (3.20%)

, ADSK

Autodesk

$81.74

1.4 (1.74%)

10:19
12/09/16
12/09
10:19
12/09/16
10:19
Upgrade
On The Fly: Top five analyst upgrades »

Catch up on today's…click here.

AZN

AstraZeneca

$27.11

0.84 (3.20%)

ADSK

Autodesk

$81.74

1.4 (1.74%)

ETN

Eaton

$69.45

0.47 (0.68%)

FLR

Fluor

$56.77

0.77 (1.38%)

SYY

Sysco

$54.46

0.13 (0.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jan

  • 09

    Jan

  • 16

    Feb

$NYE

NYSE Market Internals

10:16
12/09/16
12/09
10:16
12/09/16
10:16
Technical Analysis
NYSE market internals summary »

Breadth is bullish across…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

10:16
12/09/16
12/09
10:16
12/09/16
10:16
Technical Analysis
NASDAQ market internals summary »

Volume is light for this…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:15
12/09/16
12/09
10:15
12/09/16
10:15
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

10:15
12/09/16
12/09
10:15
12/09/16
10:15
General news
FX Action: The dollar »

FX Action: The dollar…

SDRL

Seadrill

$3.72

0.315 (9.26%)

10:14
12/09/16
12/09
10:14
12/09/16
10:14
Options
Seadrill calls active as shares rally »

Seadrill calls active as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VHC

VirnetX

$3.35

0.05 (1.52%)

10:12
12/09/16
12/09
10:12
12/09/16
10:12
Periodicals
Breaking Periodicals news story on VirnetX »

Appeals court affirms…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATH

Athene Holding

10:10
12/09/16
12/09
10:10
12/09/16
10:10
Syndicate
Breaking Syndicate news story on Athene Holding »

Athene Holding indicated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

XLF

Financial Select Sector

$23.63

-0.07 (-0.30%)

10:10
12/09/16
12/09
10:10
12/09/16
10:10
Options
$15.9M premium block in SPDR Financials »

$15.9M premium block in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
12/09/16
12/09
10:10
12/09/16
10:10
General news
U.S. December consumer sentiment surged 4.2 points to 98.0 in preliminary »

U.S. December consumer…

TEX

Terex

$32.28

-0.06 (-0.19%)

10:09
12/09/16
12/09
10:09
12/09/16
10:09
Upgrade
Terex rating change  »

Terex upgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

AZN

AstraZeneca

$27.09

0.82 (3.12%)

10:08
12/09/16
12/09
10:08
12/09/16
10:08
Hot Stocks
FDA accepts BLA for AstraZeneca's durvalumab for bladder cancer »

AstraZeneca and its…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

KO

Coca-Cola

$41.82

0.835 (2.04%)

10:04
12/09/16
12/09
10:04
12/09/16
10:04
Technical Analysis
Coca-Cola tests downtrend resistance »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.